Clark E. Tedford, Ph.D. is one of the founders of LumiThera and has served as President and CEO since the formation of the Company in 2013. Previously Dr. Tedford was Vice President and Chief Science Officer at PhotoThera, a leading LED/laser company from 2010-2012. Prior to PhotoThera, Dr. Tedford was at Omeros from 2003-2010 as Vice President, Pharmaceutical Research. Prior to Omeros, Dr. Tedford was President of Solentix, Inc. During Dr. Tedford’s 25 years in the pharmaceutical and medical device industry, he has held several scientific and executive management positions from 1993-2003 including Executive Vice President of Research and Development for Gliatech, Inc. Prior to that Dr. Tedford was at Schering-Plough Research Institute as a Principal Scientist. Dr. Tedford received his Ph.D. in pharmacology from the University of Iowa and completed his post-doctoral work in the Department of Pharmacology at the Loyola University Medical School.

Robert Dotson, MD is one of the founders of LumiThera and has served as CMO for the Company since its founding in 2013. Previously, Dr. Dotson maintained a solo Ophthalmology practice (the Refractive Surgery Center of Oak Ridge) in Tennessee for more than thirty years. He holds multiple US patents dealing with eye related devices and has been researching photobiomodulation for more than ten years. He has served in teaching positions at LMU-DeBusk College of Osteopathic Medicine (Harrogate, Tennessee), the University of Tennessee Center for Health Sciences (Memphis), and the University of Washington (Seattle). He is a co-founder of PhotoSpectra (Toronto) and Choices Anti-Aging Centers (Montana). He was awarded his MD degree at the University of Tennessee, College of Medicine (Memphis), completed his Ophthalmology Residency at the same institution, and was an Epstein Fellow under the sponsorship of the American IntraOcular Implant Society (AIOIS). He holds a BS in Zoology and Chemistry from the University of Tennessee (Knoxville) and served in the US Army Reserves Medical Corps as an Ophthalmologist with the rank of Major.

Graham Merry, MBBS is one of the founders of LumiThera and currently President of Photospectra which he founded in partnership with Dr. Robert Dotson in 2009. Prior to this he was a medical consultant to Occulogix Inc. for their pivotal phase III FDA trial of Rheopheresis for macular degeneration. He was also national medical director of the six independent private clinics of Veris Health Sciences Inc. providing this treatment to patients from all over the world. Dr. Merry has been a medical practitioner licensed in Canada and the UK for over 30 years. He graduated from the Royal London Hospital, London, U.K. in 1982. Dr. Merry has been instrumental in instigating and completing the Toronto and Oak Ridge clinical trial, which was the first globally to assess LED photobiomodulation (PBM) in dry macular degeneration.

James Carroll is one of the founders of LumiThera and currently the CEO at THOR Photomedicine Ltd., which he founded in 2007. Prior to that, Mr. Carroll was with THOR International from 1992-2007 as Director, Laser Sales. Prior to THOR International, Mr. Carroll was with Omega Universal Technologies, a laser equipment company. Mr. Carroll is an engineer and a recognized authority on photobiomodulation (PBM) mechanisms of action, dose rate effects and the measurement and reporting of parameters. Considered the “The world’s leading ambassador for photobiomodulation (PBM)” by Professor Mike Hamblin, Harvard Medical School, 2013, Mr. Carroll first stumbled upon photobiomodulation (PBM) in 1988 at Guys Hospital London where the famous anatomist Dr Mary Dyson was aiming low intensity lasers beams at cells to find out how this therapy caused wounds to heal more quickly.

Luis De Taboada is one of the founders of LumiThera and is currently Vice President of Engineering at Banyan BioMarkers. Prior to Banyan, Mr. De Taboada was Vice President of Research and Development at PhotoThera Inc, Director of Engineering at Laser Mechanisms, Engineering Manager at Medical Optics, a division of Kaiser Aerospace and Electronics where he led the development of novel Carbon Dioxide lasers, laser systems, fiber beam delivery systems, and research in head mounted displays for minimally invasive surgery. With over twenty years as a manager and active contributor to the design, fabrication, and testing of devices and systems for industrial, scientific, medical, and dental applications, Mr. De Taboada has extensive design and management experience on multi-disciplinary product development projects and system’s engineering encompassing diffractive and refractive optics, optical fibers, electro-optics, laser, RF, energy conversion, and software technologies; including designing test methods for system acceptance and compliance with FDA and EN requirements. Mr. De Taboada holds a M.S in Electrical Engineering and a B.S. in Applied Mathematics from the University of California, San Diego.